01
In-person medical evaluation
Health history, medications, contraindications, weight-related conditions and treatment goals are reviewed before medication is prescribed.
Semaglutide and tirzepatide weight-management programs with in-person evaluation, weekly clinic visits, dose review, side-effect support and ongoing provider oversight. Start with a medical consultation—not an online questionnaire.
GLP-1–based medications can help eligible patients reduce appetite and support long-term weight management when used with nutrition and physical activity. The medication is only one part of the program. Candidacy, dose escalation, side effects, nutrition and long-term planning all need medical oversight.
Health history, medications, contraindications, weight-related conditions and treatment goals are reviewed before medication is prescribed.
The source program is structured around weekly El Segundo visits rather than medication being mailed as an unsupported subscription.
Escalation depends on the medication, formulation, tolerance and provider assessment. Higher is not automatically better.
Nutrition, hydration, resistance exercise, side-effect management and long-term maintenance matter alongside the prescription.
Semaglutide is the active ingredient in FDA-approved Wegovy® for chronic weight management in qualifying patients. Compounded semaglutide is not the same as FDA-approved Wegovy and is subject to different regulatory requirements.
The original page used dose-based package names and pricing. I preserved those source tiers below for pricing continuity, but the medication, formulation and actual dose should be confirmed only after the provider evaluates you. Online payment, when offered, should remain a prepaid treatment credit—not an unconditional sale of prescription medication.
Designed to begin appetite support with weekly oversight. Starts at 0.25 mg for two weeks, then 0.5 mg for the next two. Ideal for patients beginning their GLP-1 journey.
For patients ready for steadier appetite control. Maintains 0.5 mg weekly with full medical supervision and ongoing check-ins.
Our most common plan. Maintains momentum at 1 mg weekly with professional support. Best for patients who have completed lower dose phases and are medically cleared to continue.
Stronger appetite support without large dose jumps. For patients medically cleared to advance from lower phases with weekly guidance included.
For patients who have built tolerance and been medically cleared for higher dose support. Guided care and weekly check-ins included.
Highest dose range option for patients who have built tolerance and are medically appropriate. Weekly follow-ups throughout.
Tirzepatide is the active ingredient in FDA-approved Zepbound® for chronic weight management in qualifying adults and Mounjaro® for type 2 diabetes. The old page’s statement that tirzepatide weight management is only off-label is outdated.
Zepbound uses a staged once-weekly escalation schedule. Individual treatment still depends on medical history, tolerance, indication and the formulation actually prescribed. Compounded tirzepatide is not FDA-approved Zepbound.
Introductory Tirzepatide phase at 2.5 mg weekly under full medical supervision. Designed to minimize side effects while beginning dual-hormone appetite regulation.
For patients continuing from the starter phase under provider supervision. Increased appetite regulation with structured weekly support.
Middle-range Tirzepatide dose for patients progressing through their program. Regular check-ins and monitoring ensure safety and continued progress.
For patients who have successfully completed earlier stages and been medically approved to advance. Ongoing supervision and weekly follow-ups.
For patients approved to continue at higher doses after prior stages. Weekly monitoring and personalized care focused on long-term stability.
Highest Tirzepatide dose for patients who have demonstrated tolerance and been medically approved. Maximum metabolic support with continuous professional monitoring.
The provider’s recommendation should consider indication, contraindications, prior response, side-effect history, access and the specific formulation available.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| FDA-approved weight-management brand | Wegovy® | Zepbound® |
| Source starting price | $370 / 4 weeks | $380 / 4 weeks |
| Frequency | Once weekly when prescribed as injection | Once weekly |
| Dose selection | Provider-directed escalation; formulation matters | Provider-directed escalation; formulation matters |
| Best choice | Determined after medical evaluation—not from a website comparison alone | |
The source page uses a staged timeline from evaluation through longer-term maintenance. Results and dose changes vary by patient.
Your provider reviews your health history, current medications, goals, and any contraindications. If you are a candidate, you leave with a program plan, written pricing, and your first injection the same day.
Weekly injections at starting dose. Most patients notice reduced appetite and smaller portions within the first two to three weeks. Your provider monitors tolerance and adjusts your plan as needed.
Dose is adjusted upward based on your response and tolerance. Body composition changes typically become more visible. Nutrition and hydration guidance reinforced at check-ins.
Most patients see meaningful results in this window. Your provider stabilizes you at the dose that balances results and comfort. Exit planning and lifestyle guidance support long-term consistency.
GLP-1 and GIP/GLP-1 medications have contraindications, warnings and potential adverse effects. Your provider should review the medication-specific prescribing information, your history, current medications and whether weight-management pharmacotherapy is appropriate.
Answers are general. Your provider should give medication-specific guidance based on the actual prescription.
Convenient for Manhattan Beach, Westchester, Hawthorne, Playa Vista and the LAX corridor. El Segundo visits are by appointment only.
Book your free El Segundo consultation to review candidacy, semaglutide versus tirzepatide, current pricing, medication availability and what a realistic long-term plan could look like.
Medical disclaimer: Prescription weight-management medications require evaluation by a licensed provider. FDA-approved branded products and compounded products are not interchangeable regulatory categories. Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing in the same way as approved drugs. Program pricing, formulation, sourcing and availability may change. Individual results vary. This page is informational and is not medical advice or a prescription.